Objective

To assess whether different Gd-EOB-DTPA injection rates could influence the development of artifacts during the arterial phase of liver MRI studies.

Materials and methods

All Gd-EOB-DTPA liver MRI studies performed for different clinical indications at a single tertiary referral center were retrospectively evaluated. Each examination was acquired on a 1.5 T scanner with T1 In- and Out-of-Phase, T2 with and without fat-saturation, DWI, and 3D-T1 fat-sat dynamic sequences. Patients were divided into two groups according to the injection rate (1 ml/s and 1.5 ml/s). A single radiologist recorded the presence or absence of artifacts during different acquisition phases, respectively: (1) all examination; (2) only during the arterial phase; (3) only during the portal-venous phase; (4) both in arterial and portal-venous phases. From a total of 748 MRI studies performed, 229 were excluded due to the presence of artifacts during the entire examination. The remaining 519 MRI studies were divided into two groups according to the injection rate.

Results

The first group (flow rate = 1 ml/s) was composed by 312 (60.1%) patients and the second group (flow rate = 1.5 ml/s) by 207 (39.9%) patients. In the first group, 2 (0.6%) patients showed artifacts in all dynamic sequences; 13 (4%) only in the arterial phase, 16 (5%) only in the portal-venous phase, and 38 (12%) both in arterial and portal-venous phases; a total of 243 (78%) showed no artifacts. In the second group, 3 (1.5%) patients had artifacts in all dynamic sequences, 82 (40%) only in the arterial phase, 20 (10%) only in the portal-venous phase, and 53 (25%) both in arterial and portal-venous phases; a total of 49 (23.5%) showed no artifacts. A significant difference between the two groups regarding the absence of artifacts in all examination and the presence of artifacts only during the arterial phase was found (p < 0.001).

Conclusion

The development of artifacts during the arterial phase of Gd-EOB-DTPA liver MRI studies could be related to the injection rate and its reduction may help to decrease the incidence of artifacts.

中文翻译：

---

在 Gd-EOB-DTPA MRI 研究中获取动态动脉期期间注射速率对确定伪影发展的影响。

客观的

评估不同的 Gd-EOB-DTPA 注射率是否会影响肝脏 MRI 研究动脉期伪影的发展。

材料和方法

回顾性评估了在一个三级转诊中心针对不同临床适应症进行的所有 Gd-EOB-DTPA 肝脏 MRI 研究。每次检查都是在具有 T1 同相和异相、T2 有和没有脂肪饱和度、DWI 和 3D-T1 脂肪饱和动态序列的 1.5 T 扫描仪上获得的。根据注射速度将患者分为两组（1 ml/s 和 1.5 ml/s）。单个放射科医师在不同采集阶段分别记录伪影的存在与否： (1) 所有检查；(2) 仅在动脉期；(3) 仅在门静脉期；(4) 在动脉期和门静脉期。在总共进行的 748 项 MRI 研究中，229 项由于在整个检查过程中存在伪影而被排除在外。

结果

第一组（流速 = 1 ml/s）由 312 (60.1%) 名患者组成，第二组（流速 = 1.5 ml/s）由 207 (39.9%) 名患者组成。在第一组中，2 名 (0.6%) 患者在所有动态序列中都表现出伪影；13（4%）只在动脉期，16（5%）只在门静脉期，38（12%）只在动脉期和门静脉期；总共 243 个 (78%) 没有出现伪影。在第二组中，3 名 (1.5%) 患者在所有动态序列中都有伪影，82 名 (40%) 仅在动脉期，20 名 (10%) 仅在门静脉期，53 名 (25%) 都在动脉期和门静脉期；共有 49 个 (23.5%) 没有出现伪影。发现两组在所有检查中都没有伪影和仅在动脉期出现伪影方面存在显着差异（p < 0.001)。

结论

Gd-EOB-DTPA 肝脏 MRI 研究动脉期伪影的发展可能与注射速率有关，其减少可能有助于降低伪影的发生率。